CD274 and non-small cell lung carcinoma: In the KEYNOTE-024 study of previously untreated advanced NSCLC patients with PD-L1 expression ≥ 50%, median PFS was 10.3 months with pembrolizumab versus 6.0 months with chemotherapy (HR for disease progression or death, 0.50; p < 0.001) [13].